ARTICLE | Deals
Deals Report: BMS-Repertoire to develop vaccines for autoimmunity
Plus: Regeneron, Mammoth to make CRISPR-based gene editing therapies, and updates from Vertex-TreeFrog, Ono-Deciphera and more
April 30, 2024 2:13 AM UTC
The past week saw a half dozen large biopharmaceutical companies, including BMS, Regeneron and Vertex, partner with smaller companies, and Ono and Incyte acquire biotechs in a pair of sizable deals.
Bristol Myers Squibb Co. (NYSE:BMY) and Repertoire Immune Medicines Inc. agreed to develop vaccines for up to three autoimmune diseases in a multiyear partnership. Repertoire will use DECODE, its T cell receptor epitope discovery platform, and its lipid nanoparticle delivery tech, to create therapies, and BMS will lead clinical and commercial activities under a worldwide license. Repertoire will receive $65 million up front and up to $1.9 billion in milestones, plus tiered royalties. ...